Results 101 to 110 of about 342 (145)

Nemolizumab (Nemluvio®) for prurigo nodularis

Trends in Pharmacological Sciences
Svenja, Royeck, Sonja, Ständer
openaire   +2 more sources

A case of acute generalized exanthematous pustulosis following administration of nemolizumab

JAAD Case Reports
Alyssa Khoo, BA, Elgida Volpicelli, MD, Elle de Moll, MD   +2 more
doaj   +1 more source

Novel therapeutic use of nemolizumab for refractory chronic scalp dysesthesia

JAAD Case Reports
Lauren Kuan, BA, Theodore Mah, Peter B. Chansky, MD   +2 more
doaj   +1 more source

A Case of Galactorrhea and Hyperprolactinemia Following Nemolizumab Administration

Pediatrics International
Hidemasa Sakai, Tadashi Oi, Kohei Yoshioka, Takeyasu Igarashi   +3 more
openaire   +3 more sources

Four Cases of Prurigo Nodularis Requiring Nemolizumab due to Persistent Pruritus or Lesions after Dupilumab Treatment

Acta Dermato-Venereologica
Yoshihito Mima, Masako Yamamoto, Ken Iozumi   +2 more
doaj   +1 more source

Porokeratosis ptychtropica successfully treated with nemolizumab

JAAD Case Reports
Jerald Sklar, Grace Neill, Alexandria Marrs, Prasana Sinkre   +3 more
openaire   +1 more source

Novel intralesional nemolizumab for chronic scalp prurigo nodularis

JAAD Case Reports
Gaven, Emily, Siddiqui, Sarah, Stout, Molly   +2 more
openaire   +2 more sources

The Absence of Recent Systemic Therapy can be a Significant Risk Factor for Nemolizumab-associated Cutaneous Adverse Events in Patients with Prurigo Nodularis: A Single-centre Retrospective Study

Acta Dermato-Venereologica
Yoshihito Mima, Masako Yamamoto, Ken Iozumi   +2 more
doaj   +1 more source

Real-world Clinical Efficacy and Patient-reported Treatment Satisfaction of Nemolizumab Treatment in Prurigo Nodularis

Acta Dermato-Venereologica
Yoshihito Mima, Masako Yamamoto, Ken Iozumi   +2 more
doaj   +1 more source

Rapid clinical response to nemolizumab in a patient with lichen amyloidosis

JAAD Case Reports
Kaito Iwama, Daiki Rokunohe, Kazuhito Kogawa, Eijiro Akasaka   +3 more
openaire   +3 more sources